Biomarin Pharmaceutical (BMRN) Enterprise Value (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Enterprise Value came in at -$2.2 billion in Q1 2026, down 74.67% YoY from -$8.8 billion in Q1 2025, and down 42.41% on a QoQ basis from -$1.6 billion in Q4 2025.
Biomarin Pharmaceutical (BMRN) Enterprise Value (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Enterprise Value data on file, last reported at -$2.2 billion in Q1 2026.
- Quarterly Enterprise Value fell 74.67% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 74.67% YoY) and the FY2025 annual result came in at -$1.6 billion, down 37.17% from the prior year.
- Enterprise Value slipped to -$2.2 billion in Q1 2026, from -$1.6 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$930.4 million in Q3 2024 to a low of -$2.2 billion in Q1 2026.
- A 5-year average of -$1.3 billion and a median of -$1.2 billion in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value climbed 17.36% — and 2026, when it plunged 74.67%.
- Tracing BMRN's Enterprise Value over 5 years: stood at -$1.3 billion in 2022, then rose by 16.86% to -$1.1 billion in 2023, then dropped by 5.95% to -$1.1 billion in 2024, then sank by 37.17% to -$1.6 billion in 2025, then sank by 42.41% to -$2.2 billion in 2026.
- The last three Enterprise Value figures came in at -$2.2 billion (Q1 2026), -$1.6 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | -874.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -874.01 Mn |
| Mar 31, 2026 | -2.22 Bn |
| Dec 31, 2025 | -1.56 Bn |
| Sep 30, 2025 | -1.48 Bn |
| Jun 30, 2025 | -1.43 Bn |
| Mar 31, 2025 | -1.27 Bn |
| Dec 31, 2024 | -1.14 Bn |
| Sep 30, 2024 | -930.44 Mn |
| Jun 30, 2024 | -1.22 Bn |
| Mar 31, 2024 | -1.05 Bn |
| Dec 31, 2023 | -1.07 Bn |
| Sep 30, 2023 | -1.13 Bn |
| Jun 30, 2023 | -1.17 Bn |
| Mar 31, 2023 | -1.15 Bn |
| Dec 31, 2022 | -1.29 Bn |
| Sep 30, 2022 | -1.27 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -1.06 Bn |
| Dec 31, 2021 | -1.01 Bn |
| Sep 30, 2021 | -1.08 Bn |